Comprehensive slide showing EULAR recommendations for CV risk management in patients with #gout #systemicsclerosis #vasculitis #myositis #MCTD #SLE #APS ⏬🔽⬇️
RT @md_arianemacedo: EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic…
RT @md_arianemacedo: EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic…
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome https://t.co/n7zfje0lqo
RT @athensmedschool: Ευρωπαϊκές Συστάσεις για την αντιμετώπιση του καρδιαγγειακού κινδύνου στα ρευματικά νοσήματα με επικεφαλής την Καθηγήτ…
Ευρωπαϊκές Συστάσεις για την αντιμετώπιση του καρδιαγγειακού κινδύνου στα ρευματικά νοσήματα με επικεφαλής την Καθηγήτρια της Ιατρικής Σχολής ΕΚΠΑ Μαρία Τεκτονίδου! Περισσότερες πληροφορίες: https://t.co/oghUTLfK01 https://t.co/BN1JVI5IGk
RT @MariaTektonidou: Hopefully our task force work will help improve #cardiovascular health in #RMDs: #EULAR recommendations for cardiovasc…
@eular_org recommendations for cardiovascular risk management in rheumatic & musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. A useful Guideline if seeing patients with vasculitis/APS. https://t.co/HDyau9
@eular_org recommendations for cardiovascular risk management in rheumatic & musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. A useful Guideline if seeing patients with vasculitis/APS. https://t.co/MuDV1
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @reumatologiasp: #SPRindica - Confira a parte 2 do resumo que preparamos sobre as novas recomendações do EULAR para o manejo de doenças…
RT @reumatologiasp: #SPRindica - Pesquisadores de 11 países europeus estabeleceram novas recomendações para o manejo de doenças reumáticas…
RT @LupusAcademy: @eular_org recommendations for #cardiovascular risk management in rheumatic and musculoskeletal diseases, including syste…
@eular_org recommendations for #cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic #lupus erythematosus and antiphospholipid syndrome: https://t.co/s5szlzMhSD #APS #SLE #rheumatology #RheumTwitter #CardioTwitter @A
#SPRindica - Confira a parte 2 do resumo que preparamos sobre as novas recomendações do EULAR para o manejo de doenças reumáticas e musculo-esqueléticas. Visite o nosso perfil para conferir a parte 1 Leia o estudo na íntegra: https://t.co/87iii3cZwH https
#SPRindica - Pesquisadores de 11 países europeus estabeleceram novas recomendações para o manejo de doenças reumáticas e musculo-esqueléticas. Confira o resumo que preparamos e leia o estudo na íntegra em: https://t.co/87iii3cZwH https://t.co/qOqLkltICe
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome https://t.co/zGNEYowSJ3
RT @ErnestoCairoli: AUTOINMUNES y MANEJO DEL RIESGO CARDIOVASCULAR: ACR/EULAR febrero 2022 Acá van la recomendaciones (para que pueda leer…
RT @ErnestoCairoli: MANEJO del RIESGO CARDIOVASCULAR en ENFERMEDADES AUTOINMUNES guías ACR/EULAR feb2022 EULAR recommendations for cardiov…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @MariaTektonidou: In this #EULAR Task Force we included #recommendations for #cardiovascular #risk #management in several #rheumatic dis…
RT @MariaTektonidou: In this #EULAR Task Force we included #recommendations for #cardiovascular #risk #management in several #rheumatic dis…
In this #EULAR Task Force we included #recommendations for #cardiovascular #risk #management in several #rheumatic diseases: #SLE, #APS, #vasculitis, #SSc, #myositis, #MCTD, #SS, #gout. https://t.co/oLUczKsB32
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @PamelaLutalo: In this slide @Lupusreference summarises the important EULAR recommendations for cardiovascular risk management in #SLE &…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
SLEおよび抗リン脂質症候群などのリウマチ性疾患における心血管リスク管理のための欧州リウマチ学会の推奨(全文フリー) https://t.co/2LhbTnttMu
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
RT @Lupusreference: ❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://…
❤️ EULAR recommendations for the management of #cardiovascular risk in patients with #lupus or aPL/APS 🎯 Link: https://t.co/AxsCpTXgcn https://t.co/tnsarpvrXu
🔹En LES usar la dosis mínima de corticoides posible! Hidroxicloroquina es 🔝 porque puede ⬇️RCV. No inmunosupresores específicos💊 Puedes consultar el artículo completo aquí➡️ https://t.co/rGPHPp54kN 📝 #felizjueves 🙌🏻 (🧵8de8)
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome | Annals of the Rheumatic Diseases https://t.co/nzUbavxapK
RT @MariaTektonidou: Hopefully our task force work will help improve #cardiovascular health in #RMDs: #EULAR recommendations for cardiovasc…
RT @MariaTektonidou: Hopefully our task force work will help improve #cardiovascular health in #RMDs: #EULAR recommendations for cardiovasc…
RT @MariaTektonidou: Hopefully our task force work will help improve #cardiovascular health in #RMDs: #EULAR recommendations for cardiovasc…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. 👇🏼 https://t.co/KCIJs8bTdj
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. – via @ARD_BMJ https://t.co/AbKrlMEuhe
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…
RT @ARD_BMJ: ❗ EULAR recommendations for #cardiovascular risk management in #rheumatic and musculoskeletal diseases, including systemic #lu…